Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
L3Harris (LHX) - Upgrade to Buy: steady cash, growing backlog, and a tactical swing entry
Defense contractor benefits from resilient demand and attractive risk/reward after Q3 results — tactical long with defined stops and two target levels
L3Harris reported another quarter of healthy revenues ($5.66B) and operating income ($621M) while generating positive operating cash flow. The busines...
Buy the Dip in PSEG (PEG): New Jersey Bill Backlash Creates Regulated-Utility Entry Point
Regulatory noise has pushed the stock lower; underlying cash generation, a healthy dividend and predictable rate mechanics make PEG a tactical long.
Public Service Enterprise Group (PEG) is a regulated New Jersey utility with stable cash flow, a 3%+ yield and recent quarterly earnings strength. Sho...
Risks Are Rising — But Fox Still Looks Like a Tactical Long
Ad-driven Fox has a few landmines — yet steady profitability, streaming upside and a modest valuation give room for further gains
Fox (FOX) is increasingly exposed to cyclical advertising and rights-cost pressure, but the company is profitable, producing solid operating income an...
Rimini Street: Cheap, Cash-Generating, and Poised to Re-rate
Small-cap enterprise software support business with steady subscription revenue, improving profitability and a sub-$1B valuation — a tactical long for swing traders and patient position buyers.
Rimini Street (RMNI) runs recurring enterprise support for ERP/CRM/databases, generating consistent ~ $100M quarters, strong gross margins and improvi...
Salesforce for 2026: Buy the AI-Enabled SaaS Rebound — Top Pick, Tactical Entry and Targets
Recurring revenue, margin leverage, and shareholder returns make CRM a high-conviction long despite headline 'SaaS fatigue.'
Salesforce is executing on Customer 360 + AI, reporting accelerating EPS and healthy margins while returning capital. I view the recent pullback as a ...
Standard Motor Products: Cheap Valuation, Messy Near-Term - Tactical Long with Defined Risk
Q3 noise from discontinued operations and inventory build masks a sub-$1B market cap industrial with steady cash flow and a 3.4% yield.
Standard Motor Products (SMP) is a profitable auto-parts manufacturer and distributor trading near $37 after a volatile run. The recent quarter shows ...
H&R Block: A 2026 Rebound Trade if the New CEO Delivers Operational Discipline
Seasonality creates a cheap entry today — buy into tax-season upside, guard for balance-sheet and cash-flow risk
H&R Block (HRB) is a highly seasonal cash machine that looks inexpensive today on a pre-tax-season basis. The business generates the lion's share of r...
Buy PRME: Cash Injection and Clinical Publications Create a Clear Catalyst Path
Funded runway, high R&D cadence, and Wilson's disease program make this an asymmetric long trade — enter cautiously, size for volatility.
Prime Medicine (PRME) finished Q3 2025 with a refreshed cash balance after a July financing and a steady cadence of high R&D spending. The combination...
TSMC: Reinforcing the Moat — Position Trade with Defined Risk/Reward
Buy a controlled position as manufacturing scale, customer concentration, and pricing power converge; use tight risk controls.
Taiwan Semiconductor (TSM) is trading near multi-month highs as the foundry cycle and AI-driven capex sustain demand for advanced nodes. With mid-60s ...
Zeta Global: AI + Identity Is Starting to Drive Profitability — My 2026 Small‑Cap Long Idea
Buy ZETA around $20 with a 17.50 stop; targets at $27, $35 and $50 — high conviction if execution and legal noise clear
Zeta Global is an omnichannel marketing platform built on identity data and machine learning. Recent quarters show accelerating revenue (Q3 2025 reven...
PriceSmart: Strong Run, Still Room to Run — A Cautious Long Trade
The obvious gains are behind us, but fundamentals and cash generation justify a controlled long with tight risk management.
PriceSmart (PSMT) has delivered steady revenue and cash-flow improvements across recent quarters, and while the stock has already moved materially hig...
Sight Sciences (SGHT) - Payer Wins Fuel a High-Risk, High-Reward Long: Buy the Coverage Narrative, Trim on Headline Pullbacks
Commercial payer coverage and durable clinical data are being priced into the stock; fundamentals improving but execution and reimbursement timing remain the biggest risks.
Sight Sciences has seen a dramatic share-price rerate after major payer coverage and favorable clinical/economic readouts. Revenues are roughly $18-20...